论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
单细胞测序技术进展及其在三阴性乳腺癌中的应用
Authors Li M, Yan T, Wang M, Cai Y, Wei Y
Received 16 September 2022
Accepted for publication 7 December 2022
Published 14 December 2022 Volume 2022:14 Pages 465—474
DOI https://doi.org/10.2147/BCTT.S388534
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Pranela Rameshwar
Abstract: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and is mainly treated with chemotherapy-based combination therapy. In recent years, with the increasing development of global precision medicine, single-cell sequencing (SCS) has become one of the most promising technologies in the field of biotechnology. Moreover, the related application of this technology in TNBC has been applied and developed. By using SCS to study the heterogeneity of TNBC tumor cells, metastasis, drug resistance mechanisms, mutations, and cloning; it can further guide clinical chemotherapy, targeted therapy, and immunotherapy. To further reflect the importance of SCS in TNBC, this paper elaborated on and summarized the research and application progress of SCS in TNBC.
Keywords: TNBC, SCS, heterogeneity, drug resistance, metastasis